In May of 2000 the US Food and Drug Administration approved the first therapy for women who experience reduced sensation, lubrication and ability to achieve or sustain orgasm during sex.
Thedevice known is known as the EROS Clitoral Therapy Device (EROS-CTD). The therapy is designed to treat female sexual arousal disorder, a form of female sexual dysfunction related to inadequate blood flow to the clitoris.
The EROS-CTD is available by prescription only. It works by drawing blood to the clitoris to trigger sexual arousal and enhance orgasms. In a study presentedat a conference of the American Urological Association 80% of female sexual arousal disorder sufferers reported improved sexual satisfaction after using EROS before intercourse.
The noninvasive device administers a "gentle suction" to the clitoris, which increases blood flow to the area, according tothe manufacturer, UroMetrics. When the arteries expand to accommodate the extra blood flow pressure is exerted on the clitoral nerves which can help to increase sexual arousal.
Treatmentwith the EROS-CTD may beespecially effective in post-menopausal women andwomen who have had hysterectomies.The devicecosts about $350, but it may be covered by insurance.
